Literature DB >> 28776173

Intensive versus standard lowering of blood pressure in the acute phase of intracranial haemorrhage: a systematic review and meta-analysis.

Tiziana Carandini1, Viviana Bozzano2, Elio Scarpini1, Nicola Montano3,4, Monica Solbiati3.   

Abstract

The optimal target of blood pressure (BP) in the acute phase of intracranial haemorrhage (ICH) is still controversial. Our aim was to evaluate safety and efficacy of intensive BP lowering compared to standard BP treatment in ICH. We conducted a systematic review and meta-analysis of all available randomized controlled trials recruiting patients with elevated BP in acute spontaneous ICH to intensive or standard BP-lowering treatment. Our primary outcomes were 3-month mortality, disability (modified Rankin Scale 3-5) and combined death or disability. Secondary outcomes were early neurological deterioration at 24 h, substantial haematoma enlargement within 24-72 h and 3-month non-fatal serious adverse events. We included six studies for a total of 4385 patients (mean age 62 years, 62.3% men). No differences were detected between the two treatment groups in 3-month mortality (RR = 0.99, 95% CI 0.83-1.17), disability (RR = 0.96, 95% CI 0.89-1.03) and combined death and disability (RR = 0.97, 95% CI 0.90-1.03). The rate of patients with early neurological deterioration, substantial haematoma enlargement and non-fatal serious adverse events was similar in the two treatment groups (RR = 1.03, 95% CI 0.88-1.19, RR = 0.85, 95% CI 0.70-1.03, RR = 1.07, 95% CI 0.90-1.28, respectively). An intensive BP control in the acute phase of ICH is not beneficial and should not be recommended. Therefore, the systolic BP target of less than 140 mmHg that is now suggested by guidelines needs to be reconsidered.

Entities:  

Keywords:  Blood pressure; Haemorrhagic stroke; Intensive; Intracranial bleeding; Meta-analysis; Systematic review

Mesh:

Substances:

Year:  2017        PMID: 28776173     DOI: 10.1007/s11739-017-1716-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  21 in total

Review 1.  INTERACT-2: should blood pressure be aggressively lowered acutely after intracerebral hemorrhage?

Authors:  Michael D Hill; Keith W Muir
Journal:  Stroke       Date:  2013-08-29       Impact factor: 7.914

Review 2.  Medical management of intracerebral haemorrhage.

Authors:  Floris H B M Schreuder; Shoichiro Sato; Catharina J M Klijn; Craig S Anderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-11-16       Impact factor: 10.154

3.  Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke.

Authors:  Mirza Jusufovic; Else C Sandset; Philip M W Bath; Eivind Berge
Journal:  Stroke       Date:  2014-09-25       Impact factor: 7.914

4.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

5.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo
Journal:  Stroke       Date:  2015-05-28       Impact factor: 7.914

Review 6.  Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis.

Authors:  Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn
Journal:  Lancet Neurol       Date:  2010-01-05       Impact factor: 44.182

7.  Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.

Authors:  John F Potter; Thompson G Robinson; Gary A Ford; Amit Mistri; Martin James; Julia Chernova; Carol Jagger
Journal:  Lancet Neurol       Date:  2008-12-04       Impact factor: 44.182

8.  Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry.

Authors:  Simona Sacco; Carmine Marini; Danilo Toni; Luigi Olivieri; Antonio Carolei
Journal:  Stroke       Date:  2008-11-26       Impact factor: 7.914

9.  Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.

Authors:  Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers
Journal:  Lancet Neurol       Date:  2008-04-07       Impact factor: 44.182

Review 10.  Targeting Secondary Hematoma Expansion in Spontaneous Intracerebral Hemorrhage - State of the Art.

Authors:  Jian Guan; Gregory W J Hawryluk
Journal:  Front Neurol       Date:  2016-10-25       Impact factor: 4.003

View more
  2 in total

Review 1.  Therapeutic Approach to Hypertensive Emergencies: Hemorrhagic Stroke.

Authors:  Massimo Salvetti; Anna Paini; Fabio Bertacchini; Carlo Aggiusti; Deborah Stassaldi; Laura Verzeri; Giovanni Saccà; Maria Lorenza Muiesan
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-06-04

Review 2.  Hypertensive Crisis in Acute Cerebrovascular Diseases Presenting at the Emergency Department: A Narrative Review.

Authors:  Mariagiovanna Cantone; Giuseppe Lanza; Valentina Puglisi; Luisa Vinciguerra; Jaime Mandelli; Francesco Fisicaro; Manuela Pennisi; Rita Bella; Rosella Ciurleo; Alessia Bramanti
Journal:  Brain Sci       Date:  2021-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.